摘要
目的探讨双歧杆菌三联活菌胶囊联合思密达治疗小儿腹泻的临床效果。方法从我院儿科2013年10月~2015年10月收治的腹泻患儿中随机抽取116例进行研究,并根据其入院顺序分为对照组(58例,经常规治疗)和观察组(58例,经双歧杆菌三联活菌胶囊联合思密达治疗),对比两组患儿的临床治疗效果、临床症状缓解时间和药物安全性。结果对照组有20例显效,21例有效;观察组有25例显效,29例有效;组间总有效率比较,观察组为93.10%,显著高于对照组的70.69%,组间差异有统计学意义(P〈0.05)。经比较,观察组患儿的大便好转、腹泻停止和发热消退等时间均短于对照组,组间各指标差异均显著,经统计学分析差异有统计学意义(P〈0.05)。两组患儿均未出现明显不良反应,且血尿常规和肝肾功能检查无异常,组间差异无统计学意义(P〉0.05)。结论采用双歧杆菌三联活菌胶囊和思密达对小儿腹泻进行联合治疗具有显著效果,可快速缓解临床症状,安全可靠,具有较高的临床推广价值。
Objective To explore the clinical effect of bifid triple viable capsules combined with smecta in the treatment of infantile diarrhea. Methods 10 children with diarrhea who were admitted to pediatric department of our hospital from October 2013 and 2015 were randomly selected and they were allocated to the control group(58 cases, routine treatment) and the observation group(58 cases, bifid triple viable capsules combined with smecta) according to the sequence of admission. Clinical curative effect, alleviation time of clinical symptoms and drug safety of children in two groups were compared. Results In the control group, there were 20 cases with marked effect and 21 cases with effect. In the observation group, there were 25 cases with marked effect and 29 cases with effect. The total effective rate of the observation group was 93.10 %, significantly higher than that of the control group 70.69 %. Difference between two groups was significant(P 〈0.05). By comparison, time of stool improvement, diarrhea stopping, fever alleviation and so on of children in the observation group were all shorter than those of the control group, The difference in every index between two groups was significant and the difference was statistically significant(P0.05). There were no obvious adverse reactions in the two groups and there was no abnormality in the blood urine routine test and liver-kidney function tests. There was no significant difference between two groups(P 〉0.05). Conclusion Combined treatment of bifid triple viable capsules and amecta for infantile diarrhea can rapidly alleviate clinical symptoms. It is safe and reliable and of high value clinical promotion.
出处
《中国医药科学》
2016年第6期37-39,共3页
China Medicine And Pharmacy